Pyrazinamide (PZA) is a cornerstone of modern TB chemotherapy due to its unique ability to shorten the duration of nearly all clinically used regimens. However, resistance is emerging while prospects for a replacement remain lacking, threatening the duration of all future chemotherapies. Understanding the molecular basis for the unique activity of PZA will allow development of additional regimen shortening agents that target the same pathways. However, efforts to develop a functional replacement for PZA remain hindered by fundamental gaps in our understanding of its microbiologic and biochemical targets. Here, we propose to overcome these gaps by identifying physiologic biomarkers of PZA activity and susceptibility. These studies will specifically integrate experimental studies of PZA in vitro activity with in vivo studies of PZA activity as reported by the transcriptional profiles of Mtb recovered from the lungs of infected mice or sputa of culture confirmed patients. Based on our preliminary data, these studies will also test the specific hypothesis that PZA targets Mtb subpopulations whose viability is strictly dependent on NAD salvage pathway activity. By integrating parallel in vitro and in vivo studies with hypothesis-based and unbiased approaches, this project will provide deeper insights into the target(s) and/or mechanism(s)-of-action of PZA, the specific microbiologic subpopulations it targets, and a molecular signature of its activity that can be used to facilitate the development of new agents targeting the same pathways as PZA.
Antibiotic resistance is eroding the efficacy of current treatments for tuberculosis, the leading cause of deaths due to a curable infection. This project aims to help develop a replacement for the frontline drug pyrazinamide.
|Ocheretina, Oksana; Byrt, Erin; Mabou, Marie-Marcelle et al. (2016) False-positive rifampin resistant results with Xpert MTB/RIF version 4 assay in clinical samples with a low bacterial load. Diagn Microbiol Infect Dis 85:53-5|
|Warrier, Thulasi; Kapilashrami, Kanishk; Argyrou, Argyrides et al. (2016) N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 113:E4523-30|
|Glickman, Michael S; Schluger, Neil (2016) Adding Insult to Injury: Exacerbating TB Risk with Smoking. Cell Host Microbe 19:432-3|
|Gold, Ben; Smith, Robert; Nguyen, Quyen et al. (2016) Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosis. J Med Chem 59:6027-44|
|Lupoli, Tania J; Fay, Allison; Adura, Carolina et al. (2016) Reconstitution of a Mycobacterium tuberculosis proteostasis network highlights essential cofactor interactions with chaperone DnaK. Proc Natl Acad Sci U S A 113:E7947-E7956|
|Nathan, Carl (2015) What can immunology contribute to the control of the world's leading cause of death from bacterial infection? Immunol Rev 264:2-5|
|Nathan, Carl; Barry 3rd, Clifton E (2015) TB drug development: immunology at the table. Immunol Rev 264:308-18|
|Ocheretina, Oksana; Shen, Lishuang; Escuyer, Vincent E et al. (2015) Whole Genome Sequencing Investigation of a Tuberculosis Outbreak in Port-au-Prince, Haiti Caused by a Strain with a ""Low-Level"" rpoB Mutation L511P - Insights into a Mechanism of Resistance Escalation. PLoS One 10:e0129207|
|Gold, Ben; Roberts, Julia; Ling, Yan et al. (2015) Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:6521-38|
|Severe, Linda; Fitzgerald, Daniel W; Deschamps, Marie M et al. (2014) ""I am proud of myself, just the way I am"" (Mwen fyÃ© de tÃ©t mwen, jan mwen ye ya): a qualitative study among young Haitian women seeking care for sexually transmitted infections (STIs) in Haiti. AIDS Educ Prev 26:158-69|